Steve W Mifflin, Alison Strack. Show Affiliations »
Abstract
Mesh： See more » AnimalsAnti-Obesity Agents/pharmacologyAnti-Obesity Agents/therapeutic useCentral Nervous System/drug effectsCentral Nervous System/metabolismCentral Nervous System/physiopathologyCyclohexanes/pharmacologyCyclohexanes/therapeutic useEnergy Metabolism/drug effectsFeeding BehaviorHumansLeptin/metabolismObesity/drug therapyObesity/metabolismObesity/physiopathologyPyrazoles/pharmacologyPyrazoles/therapeutic useReceptors, Leptin/metabolismReceptors, Neuropeptide Y/antagonists & inhibitorsReceptors, Neuropeptide Y/metabolismSignal Transduction/drug effectsSpiro Compounds/pharmacologySpiro Compounds/therapeutic useWeight Gain
Substances： See more » Anti-Obesity AgentsCyclohexanesLeptinPyrazolesReceptors, LeptinReceptors, Neuropeptide YSpiro Compoundsneuropeptide Y5 receptorspiro(cyclohexane-1,3'(1'H)-furo(3,4-C)pyridine)-4-carboxamide, N-(1-(2-fluorophenyl)-1h-pyrazol-3-yl)-1'-oxo-, trans-
Year: 2007 PMID： 17766646 PMCID： PMC2277037 DOI： 10.1113/jphysiol.2007.140566
Source DB: PubMed Journal: J Physiol ISSN： 0022-3751 Impact factor: 5.182